Cancer Blood Test

A well-known private healthcare group, Fortis on Friday inaugurated a state-of-the-art facility for the specialised treatment of blood cancers and disorders, which it said "represented a critical step" in addressing the urgent need for comprehensive holistic care. The Fortis Institute of Blood Disorders also integrates paediatric and geriatric care, advanced transplant procedures, and hematopathology expertise, all under one roof, Fortis Healthcare said in a release. The Institute also launched CAR-T cell therapy to its extensive network of Bone Marrow Transplant centres in Mohali, Delhi, Gurgaon, Noida, Mumbai and Bangalore, the statement said. This initiative is supported by a commercial collaboration with ImmunoACT, an IIT-Bombay spin-off and pioneer in India's first fully indigenous and commercially approved gene-modified cell therapy. The NexCAR19, India's first market-authorised CAR-T cell therapy, offers a new ray of hope for treating B-cell lymphomas and B-acute lymphoblast

A National Health Service (NHS) trial of a new blood test for more than 50 types of cancer has shown promise after it correctly revealed two out of every three cancers in people who had visited their general practitioner (GP) with suspected symptoms in England or Wales, the University of Oxford researchers said on Friday. The so-called Galleri test also correctly identified the original site of cancer in 85 per cent of those cases in what has been described as the first large-scale evaluation of a multi-cancer early detection (MCED) test in individuals who presented to their GP for diagnostic follow-up for suspected cancer. The SIMPLIFY study enrolled 6,238 patients, aged 18 and older, who were referred for urgent imaging, endoscopy or other diagnostic modalities to investigate symptoms suspicious for possible gynaecological, lung, lower GI or upper GI cancer, or who had presented with non-specific symptoms. New tools that can both expedite cancer diagnosis and potentially avoid ...

The company's OncoVeryx-F is a patented technology that combines metabolomics (study of small molecules) and AI to identify metabolite signatures of multiple cancers in a single test

Cancers of ovary, liver, stomach, pancreas, esophagus, colorectum, lung or breast were detected

The test requires a fraction of a tube of blood and can detect genetic mutations in DNA